| Identification | Back Directory | [Name]
1-Piperazineacetamide, 4-(5-fluoro-2-pyridinyl)-N-(4,5,6,7-tetrahydro-2-benzothiazolyl)- | [CAS]
1431945-95-7 | [Synonyms]
FATP1-IN-1
1-Piperazineacetamide, 4-(5-fluoro-2-pyridinyl)-N-(4,5,6,7-tetrahydro-2-benzothiazolyl)- | [Molecular Formula]
C18H22FN5OS | [MOL File]
1431945-95-7.mol | [Molecular Weight]
375.46 |
| Chemical Properties | Back Directory | [density ]
1.349±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 62.5 mg/mL (166.46 mM; Need ultrasonic) | [form ]
Solid | [pka]
8.76±0.20(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
FATP1-IN-1 (compound 5k) is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC50 values of 0.046 μM or 0.60 μM, respectively[1]. | [Biological Activity]
FATP1-IN-1 is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC50 values of 0.046 μM or 0.60 μM, respectively[1].
FATP1-IN-1 (p.o.; 10 mg/kg) treatment shows the Cmax, AUC and Tmax were 5.5 μg/mL, 36 μg h/mL and 0.33 hours, respectively, and exceeds the mouse IC50 value of 0.22 μM without considering plasma protein binding. | [in vivo]
FATP1-IN-1 (p.o.; 10 mg/kg) treatment shows the Cmax, AUC and Tmax were 5.5 μg/mL, 36 μg h/mL and 0.33 hours, respectively, and exceeds the mouse IC50 value of 0.22 μM without considering plasma protein binding. | Animal Model: | Mouse plasma[1] | | Dosage: | 10 mg/kg | | Administration: | P.o. | | Result: | The Cmax, AUC and Tmax were 5.5 μg/mL, 36 μg h/mL and 0.33 hours, respectively. |
| [References]
[1]. Matsufuji T, et al. Arylpiperazines as fatty acid transport protein 1 (FATP1) inhibitors with improved potency and pharmacokinetic properties. Bioorg Med Chem Lett. 2013;23(9):2560-2565. |
|
|